NCT04075240View on ClinicalTrials.gov

VTE Prevention Following Total Hip and Knee Arthroplasty

PHASE3RecruitingINTERVENTIONAL
Enrollment

5,400

Participants

Timeline

Start Date

February 4, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

April 30, 2026

Conditions
Venous Thromboembolism
Interventions
DRUG

Rivaroxaban 10 MG and acetylsalicylic acid 81 mg

Starting post op, rivaroxaban (5 days) followed by aspirin (9 days for TKA; 30 days for THA)

DRUG

acetylsalicylic acid 81 mg

Starting post op, aspirin for 9 days for TKA and 30 days for THA

Trial Locations (1)

B3H 3A7

RECRUITING

Queen Elizabeth II HSC, Halifax

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Nova Scotia Health Authority

OTHER

collaborator

Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network

NETWORK

lead

Sudeep Shivakumar

OTHER